Birch Capital Management LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Birch Capital Management LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 0.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,956 shares of the company’s stock after selling 100 shares during the quarter. Johnson & Johnson accounts for about 2.2% of Birch Capital Management LLC’s investment portfolio, making the stock its 19th biggest holding. Birch Capital Management LLC’s holdings in Johnson & Johnson were worth $2,951,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Trust Asset Management LLC grew its holdings in shares of Johnson & Johnson by 80.5% in the third quarter. Trust Asset Management LLC now owns 13,363 shares of the company’s stock worth $1,989,000 after acquiring an additional 5,960 shares during the period. Polar Capital LLP grew its holdings in shares of Johnson & Johnson by 657.6% in the third quarter. Polar Capital LLP now owns 1,207,177 shares of the company’s stock worth $179,725,000 after acquiring an additional 1,047,825 shares during the period. OLD Mission Capital LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth $362,000. Global Trust Asset Management LLC grew its holdings in shares of Johnson & Johnson by 3.1% in the third quarter. Global Trust Asset Management LLC now owns 5,504 shares of the company’s stock worth $811,000 after acquiring an additional 166 shares during the period. Finally, Te Ahumairangi Investment Management Ltd bought a new stake in shares of Johnson & Johnson in the third quarter worth $5,694,000. Hedge funds and other institutional investors own 67.25% of the company’s stock.

Shares of NYSE:JNJ traded up $0.31 during mid-day trading on Thursday, reaching $163.92. The stock had a trading volume of 39,577 shares, compared to its average volume of 8,177,090. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The company has a market cap of $431.55 billion, a P/E ratio of 25.76, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 1 year low of $133.65 and a 1 year high of $173.65. The business’s 50 day moving average price is $161.06 and its 200 day moving average price is $154.38.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Monday, January 25th. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.82 by $0.04. The company had revenue of $22.50 million for the quarter, compared to the consensus estimate of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.88 earnings per share. Analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

Several brokerages recently commented on JNJ. SVB Leerink lifted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. Morgan Stanley boosted their price target on Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a report on Wednesday, January 27th. Raymond James boosted their price target on Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. Cantor Fitzgerald boosted their price target on Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, January 26th. Finally, JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $157.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, January 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $178.60.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Market Perform

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.